4
Changes in Ownership
Contineum Therapeutics, Inc. Filed Acc 0001628280-26-047909
Chief Scientific Officer sold 1,040 shares at $16.00 ($16,640)
- Chief Scientific Officer acquired 1,040 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
Table I: Non-derivative
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Lorrain Daniel S. Chief Scientific Officer | 2026-07-08 | Option exercise 10b5-1 | +1,015 | $1.01 | $1,025 | 136,217 | D: show line 1 in the form |
| Lorrain Daniel S. Chief Scientific Officer | 2026-07-08 | Sale 10b5-1 | −1,015 | $16.00 | $16,240 | 135,202 | D: show line 2 in the form |
| Lorrain Daniel S. Chief Scientific Officer | 2026-07-09 | Option exercise 10b5-1 | +25 | $1.01 | $25 | 135,227 | D: show line 3 in the form |
| Lorrain Daniel S. Chief Scientific Officer | 2026-07-09 | Sale 10b5-1 | −25 | $16.00 | $400 | 135,202 | D: show line 4 in the form |
| Open-market sales · 1,040 sh · avg $16.00 · $16,640 | |||||||
Table II: Derivative
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Lorrain Daniel S. Chief Scientific Officer | 2026-07-08 | Option exercise · Stock Option (right to buy) 10b5-1 | −1,015 | 33,282 | D: show line 5 in the form | ||
| Lorrain Daniel S. Chief Scientific Officer | 2026-07-09 | Option exercise · Stock Option (right to buy) 10b5-1 | −25 | 33,257 | D: show line 6 in the form |
Loading xslF345X06/wk-form4_1783718438.xml…